Tech Company Financing Transactions
GenSight Biologics Funding Round
On 7/17/2025, GenSight Biologics secured $580 thousand in funding from private investors.
Transaction Overview
Company Name
Announced On
7/17/2025
Transaction Type
Venture Equity
Amount
$580,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to ensure its operational continuity, support the finalization of manufacturing transfer activities and secure the preparations for the anticipated opening of compassionate use access in France as well as the initiation of the Phase III study RECOVER.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
74, rue du Faubourg Saint-Antoine
Paris, 75012
France
Paris, 75012
France
Phone
Undisclosed
Website
Email Address
Overview
We are a gene therapy company seeking to apply pathbreaking science to help patients with severe inherited diseases of the eye and central nervous system. Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurence Rodriguez
Browse more venture capital transactions:
Prev: 7/17/2025: Blockskye venture capital transaction
Next: 7/17/2025: Empirical Security venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs